Anesth Analg 2005;101:629-634
© 2005 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000175216.53374.27
CARDIOVASCULAR ANESTHESIA
Hydroxyethyl Starch 130/0.4 Versus Modified Fluid Gelatin for Volume Expansion in Cardiac Surgery Patients: The Effects on Perioperative Bleeding and Transfusion Needs
Philippe J. Van der Linden, MD, PhD*,
Stefan G. De Hert, MD, PhD ,
Dirk Deraedt, MD ,
Stefanie Cromheecke, MD ,
Koen De Decker, MD ,
Rudi De Paep, MD ,
Inez Rodrigus, MD, PhD ,
Anne Daper, MD*, and
Anne Trenchant, MD*
*Department of Anesthesiology, CHU Charleroi, Belgium; Department of Anesthesiology, Department of Intensive Care, Department of Cardiac Surgery, University Hospital, Antwerp, Belgium
Address correspondence and reprint requests to Philippe J. Van der Linden, MD, PhD, Department of Anesthesiology, CHU Brugmann HUDERF, 4 place Van Gehuchten, B-1020 Brussels, Belgium. Address electronic mail to philippe.vanderlinden{at}chu-brugmann.be.
In this prospective, randomized, open controlled study we compared the effects on net red blood cell loss of 6% hydroxyethyl starch 130/0.4 (HES: n = 64) and 3% modified fluid gelatin (GEL: n = 68) administered for intravascular volume management in patients undergoing coronary surgery. Blood losses were calculated from determination of circulating blood volume and measurement of preoperative and postoperative hematocrit. Amount of colloids that could be administered was limited to 50 mL/kg. If additional fluids were required, balanced crystalloid solution was used. Anesthetic and surgical techniques were standardized. Both groups were similar with regard to demographic and intraoperative variables. Total study drug was 48.9 ± 17.2 mL/kg in the HES group and 48.9 ± 14.6 mL/kg in the GEL group. Total red blood cell loss was 544 ± 305 mL in the HES group and 504 ± 327 mL the GEL group. Measured blood losses were also similar in both groups (HES, 19.4 ± 12.3 mL/kg; GEL, 19.2 ± 14.5 mL/kg). Exposure to allogeneic blood product was comparable in both groups. In the conditions of the present study, HES 130/0.4 up to 50 mL/kg is a valuable alternative to modified fluid gelatin for plasma volume expansion during and after cardiac surgery.
This article has been cited by other articles:

|
 |

|
 |
 
J. Ooi Su Min, A. R. M. Ramzisham, and M. D. Zamrin
Is 6% Hydroxyethyl Starch 130/0.4 Safe in Coronary Artery Bypass Graft Surgery?
Asian Cardiovasc Thorac Ann,
August 1, 2009;
17(4):
368 - 372.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Tritapepe, V. De Santis, D. Vitale, F. Guarracino, F. Pellegrini, P. Pietropaoli, and M. Singer
Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery
Br. J. Anaesth.,
February 1, 2009;
102(2):
198 - 204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Kozek-Langenecker, C. Jungheinrich, W. Sauermann, and P. Van der Linden
The Effects of Hydroxyethyl Starch 130/0.4 (6%) on Blood Loss and Use of Blood Products in Major Surgery: A Pooled Analysis of Randomized Clinical Trials
Anesth. Analg.,
August 1, 2008;
107(2):
382 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H Boks, M. J Wijers, J. Hofland, J. J M Takkenberg, and A. J J Bogers
Low molecular starch versus gelatin plasma expander during CPB: does it make a difference?
Perfusion,
September 1, 2007;
22(5):
333 - 337.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hitosugi, T. Saito, S. Suzuki, I. Kubota, E. Shoda, T. Shimizu, and Y. Oi
Hydroxyethyl Starch: The Effect of Molecular Weight and Degree of Substitution on Intravascular Retention In Vivo
Anesth. Analg.,
September 1, 2007;
105(3):
724 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|